CLEVELAND — Five years ago the paradigm between diagnostic firms and pharmaceutical companies was quite different. In an exclusive interview during the recent Cleveland Clinic Medical Innovation Summit and working off the backdrop of this year's theme, "Now it's personal, Cancer Treatment and Personalized Medicine," Myriad Genetics Inc.'s president, Mark Capone, spoke of the broadening reach of diagnostic solutions.